FAP and Parkinson disease: In view of the in vitro results described above and recent studies showing a therapeutic effect for CLR01 in animal models of Alzheimer’s disease (AD) [23] and Parkinson’s disease [35], we examined the impact of CLR01 on pathogenic TTR deposition in a mouse model of FAP [17] at early stages of disease.